Commentary

Anne Plested
Traders Magazine Online News

Bottlenecks Ahead

Anne Plested, head of Fidessa's EU Regulation Change programme, has written a short blog arguing that although we should be thankful that ESMA have taken a pragmatic approach to moving things along, more bottlenecks could appear in the future.

Traders Poll

Would you feel better if the Chicago Stock Exchange were purchased by U.S. firm or consortium rather than a foreign one?




Free Site Registration

July 31, 2000

IPO Roundup: The Investors' Bad Genes

By Omar Sacirbey

Also in this article

  • IPO Roundup: The Investors' Bad Genes

One of the greatest discoveries of our time - the blueprint of the human code - may take as long as 20 years to generate primal matter called long-term profits.

"Investors are still uneducated about what genomics means," said analyst Berry Summerour of the Life Sciences Research Group at Stephens Inc. "That's a big problem."

The breakthrough by erstwhile rivals, the Human Genome Project and Celera Genomics, will help revolutionize health sciences, potentially eliminating a variety of life-threatening diseases. "The language in which God created life" is how President Clinton described the discovery.

But in the short-term investors should be warned: Owning shares in genome-related companies won't make them very rich, several biotechnology analysts say. For starters, biotechnology analysts note, not all genomics-related companies will be winners. Most of the winners, moreover, won't yield dividends for at least five, 10 or even possibly 20 years, they believe.

"People were very excited about the project," said Sharon Seiler, vice president in the biotechnology department at Punk, Ziegel & Co. "Because of the media hype people were led to believe that these companies were going have a slew of discoveries of these blockbuster drugs. But that won't happen in the next one or two years."

Seiler, who worked as a lab researcher before becoming a stock analyst, added, "There's a lot of misunderstanding as to what [the genome discovery] seems to lead to."

Summerour says the process from the completion of the human genetic code - the Human Genome Project - to the creation of profitable investments will be lengthy. So lengthy, in fact, that she compares it to an hourglass.

The assembly of the human genome is in the top part of the hourglass. The narrow middle of the hourglass is some years away, as companies begin to transform information provided by the sequence into ideas that they will inevitably try to rush to market. The bottom part - the actual pay off - will be the ideas coming to fruition in the form of newly-discovered drugs based on genome sequencing information.

"The genome sequence does not by itself provide [investor] value," Summerour said. "Identifying gene function - that's where the value lies."

What companies will reap profits from the Human Genome Project? "The companies I like are the ones that will sell drugs and have the strongest biology programs," Seiler said. "They'll be able to provide revenue and margins."

Some of these companies are Arena Pharmaceuticals (Nasdaq: ARNA), Argonaut Technologies (Nasdaq: AGNT), Transgenomic Inc. (Nasdaq: TBIO), Variagenics (Nasdaq: VGNX). As of the end of July, these companies were trading in price ranges of 20 to 25.

Stratogene Holding Corp. (proposed Nasdaq: STGN), which is attempting to use genome sequence variations to see how humans and other organisms respond to drug therapies, is described by Seiler as "interesting, but a long-term prospect."

Summerour thinks that the successful companies will have the tools to analyze genome sequences. Other biotech companies worth watching are those involved in partnerships with pharmaceutical giants.